NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
Key Highlights
- ➤First child treated with NEO100 is breathing independently without ventilator support
- ➤Patient is beginning to move his legs after compassionate-use treatment
- ➤NEO100 remains investigational; pediatric safety and efficacy are unestablished
- ➤Abu Dhabi granted IND authorization across NEO100-01, NEO100-02 and NEO100-03 protocols
Expert Statements
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc
“Hearing that this little boy is breathing on his own and beginning to move his legs is profoundly moving. For his family, every sign of progress matters.”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc
“We remain cautious about these early observations and deeply grateful to his physicians and our partner, the Department of Health – Abu Dhabi, for making access to treatment possible.”
Thomas Chen, Founder, Chief Medical Officer and Chief Scientific Officer of NeOnc
“The improvements reported by this child’s treating physicians are encouraging, and continued clinical observation is essential to understand his progress.”
Thomas Chen, Founder, Chief Medical Officer and Chief Scientific Officer of NeOnc
“This individual experience does not establish safety or efficacy. Our pediatric clinical program is designed to evaluate NEO100 systematically in children with serious brain tumors.”
CALABASAS, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced early clinical improvement in its first patient treated in Abu Dhabi, United Arab Emirates, with investigational intranasal NEO100 through the Company’s Compassionate Care program. According to his treating physicians, the patient, a critically ill three-year-old boy with an aggressive brain tumor, is now breathing independently without ventilator support and beginning to move his legs following initiation of treatment. These early observations involve one patient receiving compassionate-use treatment and do not establish that NEO100 caused the improvement or predict outcomes in other patients.
“Hearing that this little boy is breathing on his own and beginning to move his legs is profoundly moving. For his family, every sign of progress matters,” said Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. “We remain cautious about these early observations and deeply grateful to his physicians and our partner, the Department of Health – Abu Dhabi, for making access to treatment possible.”
Get started
Create a free account to read the full story.